AGENUS INC Payments to Acquire Available-for-sale Securities
AGENUS INC (AGEN) reported Payments to Acquire Available-for-sale Securities of $14.94 million for the 12-month period ending 2017-12-31, per its 10-K filed 2020-03-16.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecurities · last filed 2020-03-16
- AGENUS INC payments to acquire available-for-sale securities for the quarter ending 2016-03-31 was $34.92M.
- AGENUS INC payments to acquire available-for-sale securities for the quarter ending 2015-12-31 was $19.99M.
- AGENUS INC payments to acquire available-for-sale securities for the quarter ending 2015-09-30 was $8.74K.
- AGENUS INC payments to acquire available-for-sale securities for the quarter ending 2015-06-30 was $15.00M.
- AGENUS INC payments to acquire available-for-sale securities for fiscal 2017 was $14.94M, a 72.79% decline from fiscal 2016.
- AGENUS INC payments to acquire available-for-sale securities for fiscal 2016 was $54.88M, a 56.84% increase from fiscal 2015.
- AGENUS INC payments to acquire available-for-sale securities for fiscal 2015 was $34.99M, a 141.20% increase from fiscal 2014.
- AGENUS INC payments to acquire available-for-sale securities for fiscal 2014 was $14.51M.
| Period end | Payments to Acquire Available-for-sale Securities 3 month | Payments to Acquire Available-for-sale Securities 6 month | Payments to Acquire Available-for-sale Securities 9 month | Payments to Acquire Available-for-sale Securities 12 month | Payments to Acquire Available-for-sale Securities 12 month as first filed |
|---|---|---|---|---|---|
| 2017-12-31 | $14.94M 10-K · filed 2020-03-16 | $14.94M 10-K · filed 2018-03-16 | |||
| 2016-12-31 | $54.88M 10-K · filed 2019-03-18 | ||||
| 2016-03-31 | $34.92M 10-Q · filed 2016-05-09 | $54.91M derived: sum of 2 quarters · filed 2018-03-16 | $54.92M derived: sum of 3 quarters · filed 2018-03-16 | $69.92M derived: sum of 4 quarters · filed 2018-03-16 | |
| 2015-12-31 | $19.99M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $20.00M derived: sum of 2 quarters · filed 2018-03-16 | $34.99M derived: sum of 3 quarters · filed 2018-03-16 | $34.99M 10-K · filed 2018-03-16 | |
| 2015-09-30 | $8.74K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | $15.01M derived: sum of 2 quarters · filed 2015-11-04 | $15.01M 10-Q · filed 2015-11-04 | $15.00M derived: sum of 4 quarters · filed 2017-03-16 | |
| 2015-06-30 | $15.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-03 | $15.00M 10-Q · filed 2015-08-03 | $14.99M derived: sum of 3 quarters · filed 2017-03-16 | $14.96M derived: sum of 4 quarters · filed 2017-03-16 | |
| 2015-03-31 | $0.00 10-Q · filed 2016-05-09 | -$9.84K derived: sum of 2 quarters · filed 2017-03-16 | -$35.63K derived: sum of 3 quarters · filed 2017-03-16 | ||
| 2014-12-31 | -$9.84K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | -$35.63K derived: sum of 2 quarters · filed 2017-03-16 | $14.51M 10-K · filed 2017-03-16 | ||
| 2014-09-30 | -$25.80K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | $14.52M 10-Q · filed 2015-11-04 | |||
| 2014-06-30 | $14.54M 10-Q · filed 2015-08-03 | ||||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | $0.00 derived: sum of 2 quarters · filed 2015-03-16 | $0.00 10-K · filed 2015-03-16 | ||
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-31 | $0.00 10-Q · filed 2014-10-31 | |||
| 2013-06-30 | $0.00 10-Q · filed 2014-08-01 | ||||
| 2012-12-31 | $0.00 10-K · filed 2015-03-16 | ||||
| 2012-03-31 | $0.00 10-Q · filed 2012-05-09 | $0.00 derived: sum of 2 quarters · filed 2014-03-07 | $0.00 derived: sum of 3 quarters · filed 2014-03-07 | $0.00 derived: sum of 4 quarters · filed 2014-03-07 | |
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-07 | $0.00 derived: sum of 2 quarters · filed 2014-03-07 | $0.00 derived: sum of 3 quarters · filed 2014-03-07 | $5.00M 10-K · filed 2014-03-07 | |
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | $0.00 derived: sum of 2 quarters · filed 2012-11-07 | $5.00M 10-Q · filed 2012-11-07 | $5.00M derived: sum of 4 quarters · filed 2013-03-18 | |
| 2011-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-08 | $5.00M 10-Q · filed 2012-08-08 | $5.00M derived: sum of 3 quarters · filed 2013-03-18 | $15.00M derived: sum of 4 quarters · filed 2013-03-18 | |
| 2011-03-31 | $5.00M 10-Q · filed 2012-05-09 | $5.00M derived: sum of 2 quarters · filed 2013-03-18 | $15.00M derived: sum of 3 quarters · filed 2013-03-18 | ||
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | $10.00M derived: sum of 2 quarters · filed 2013-03-18 | $29.99M 10-K · filed 2013-03-18 | ||
| 2010-09-30 | $10.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | $29.99M 10-Q · filed 2011-11-04 | |||
| 2010-06-30 | $19.99M 10-Q · filed 2011-08-05 | ||||
| 2009-12-31 | $29.99M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |